Literature DB >> 15295275

Measuring very low density lipoprotein-triglyceride kinetics in man in vivo: how different the various methods really are.

Faidon Magkos1, Labros S Sidossis.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to briefly outline the methods that are currently available for the determination of very low density lipoprotein-triglyceride (VLDL-TG) kinetics in man in vivo. RECENT
FINDINGS: A number of novel methodologies have been developed over the years for quantifying VLDL-TG production, clearance, and turnover rates. Besides the splanchnic arteriovenous balance technique, tracer methods with radioactive and, more recently, stable isotopes have been widely used. Most of the latter approaches utilize an isotopically labelled substrate, such as glycerol, fatty acid or acetate, which is eventually incorporated into a VLDL-TG moiety, and monitor the time course of change in specific activity or enrichment. A procedure of in vivo labelling of VLDL-TG with stable isotopes and use of the labelled VLDL-TG as a tracer has also been described in man. There is, however, considerable variability in estimates of VLDL-TG kinetics obtained by the various techniques, which cannot be readily attributed to normal physiological variation. Still, a large part of this discrepancy may be related to differences in VLDL-TG pool size within the normal range, which seem to account for approximately 40-50% of the total variance in VLDL-TG kinetics in both men and women.
SUMMARY: Several methods are available for quantifying VLDL-TG kinetics in man in vivo, varying in the selection of tracer, mode of administration and sampling, and data analysis. These inherent features, along with different pool sizes, result in multifold variable estimations of VLDL-TG kinetic parameters.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295275     DOI: 10.1097/00075197-200409000-00007

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  9 in total

1.  Real-time magnetic resonance imaging and quantification of lipoprotein metabolism in vivo using nanocrystals.

Authors:  Oliver T Bruns; Harald Ittrich; Kersten Peldschus; Michael G Kaul; Ulrich I Tromsdorf; Joachim Lauterwasser; Marija S Nikolic; Birgit Mollwitz; Martin Merkel; Nadja C Bigall; Sameer Sapra; Rudolph Reimer; Heinz Hohenberg; Horst Weller; Alexander Eychmüller; Gerhard Adam; Ulrike Beisiegel; Joerg Heeren
Journal:  Nat Nanotechnol       Date:  2009-01-25       Impact factor: 39.213

2.  Triglycerides produced in the livers of fasting rabbits are predominantly stored as opposed to secreted into the plasma.

Authors:  Demidmaa Tuvdendorj; Xiao-jun Zhang; David L Chinkes; Lijian Wang; Zhanpin Wu; Noe A Rodriguez; David N Herndon; Robert R Wolfe
Journal:  Metabolism       Date:  2015-01-08       Impact factor: 8.694

3.  Suppression in growth hormone during overeating ameliorates the increase in insulin resistance and cardiovascular disease risk.

Authors:  Andrea S Cornford; Ariel L Barkan; Alexander Hinko; Jeffrey F Horowitz
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-09-25       Impact factor: 4.310

4.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

Review 5.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

6.  Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo.

Authors:  Faidon Magkos; Bettina Mittendorfer
Journal:  Clin Lipidol       Date:  2009-04-01

7.  Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men.

Authors:  Lars P Sørensen; Iben R Andersen; Esben Søndergaard; Lars C Gormsen; Ole Schmitz; Jens S Christiansen; Søren Nielsen
Journal:  Diabetes       Date:  2010-09-21       Impact factor: 9.461

8.  Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men.

Authors:  Lars P Sørensen; Esben Søndergaard; Birgitte Nellemann; Jens S Christiansen; Lars C Gormsen; Søren Nielsen
Journal:  Diabetes       Date:  2011-08-01       Impact factor: 9.461

Review 9.  From Dietary Cholesterol to Blood Cholesterol, Physiological Lipid Fluxes, and Cholesterol Homeostasis.

Authors:  Frans Stellaard
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.